尤瑞克林治疗急性脑梗死临床疗效分析

Clinical Efficacy Analysis of Urinary Kallikrein in Patients With Acute Cerebral Infarction

目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法将86例急性脑梗死患者随机分为对照组和尤瑞克林治疗组,两组均给予抗血小板聚集、控制血压等常规治疗,治疗组加用0.9%生理盐水100 ml+尤瑞克林0.15 U静脉滴注,每日1次,连续治疗14 d。观察两组患者治疗前及治疗14 d后神经功能缺损程度、临床疗效及生化指标变化。结果经尤瑞克林治疗14 d后,治疗组神经功能恢复优于对照组,两组间神经功能评分差异有统计学意义(P<0.05);治疗组治疗前后实验室指标变化差异无统计学意义(P>0.05)。结论尤瑞克林治疗急性脑梗死安全、有效。

Objective To investigate the efficacy and security of Urinary Kallikrein in patients with acute cerebral infarction（ACI）. Methods 86 ACI patients were randomly divided into the control group and the Urinary Kallikrein group. Both groups of patients were received conventional therapy,such as anti-platelet aggregation and control of blood pressure. Besides the conventional therapy,the patients in the Urinary Kallikrein group also received Urinary Kallikrein treatment for 14 days. The patients were evaluated by the neurologic function score,therapeutic efficiency and biochemical indicator before and after 14 days therapy. Results The neurologic functional recovery of the Urinary Kallikrein group was obviously surpassed than that of the control group. There was significantly different between the two groups after 14 days therapy in the neurologic function score and the total efficiency（P〈0.05）. In the Urinary Kallikrein group,there was not significantly different between before and after 14 days therapy in biochemical indicator（P〈0.05）. Conclusion Urinary Kallikrein treatment on acute cerebral infarction was safe and effective.